Evidence map›Paper›PMID 32543247›Full record

Trial reportPlatelets2021

Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention.

Wael Sumaya, William A E Parker, Heather M Judge, Ian R Hall, Rachel C Orme, Zulfiquar Adam, James D Richardson, Alexander M K Rothman, Kenneth P Morgan, Julian P Gunn and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Platelets, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Wael SumayaDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
William A E ParkerDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-7822-8852
Heather M JudgeDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Ian R HallDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Rachel C OrmeDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Zulfiquar AdamDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
James D RichardsonDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Alexander M K RothmanDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Kenneth P MorganDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Julian P GunnDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Robert F StoreyDepartment of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
Northern General Hospital · GBUniversity of Sheffield · GB

Funding

British Heart Foundation FS/15/82/31824British Heart Foundation FS/18/49/33752Medical Research Council MC_PC_16058
6 · The paper itself

Abstract

A novel enoxaparin regimen consisting of intra-arterial bolus (0.75 mg/kg) followed by intravenous infusion (0.75 mg/kg/6 hours) has been developed as a possible solution to the delayed absorption of oral P2Y

Indexed as

EnoxaparinFeasibility StudiesFemaleFibrinolytic AgentsHumansMaleOpiate AlkaloidsPercutaneous Coronary InterventionEnoxaparinFibrinolytic AgentsOpiate AlkaloidsEnoxaparinglycoprotein IIb/IIIa inhibitorsP2Y12 inhibitorprimary percutaneous coronary interventionST-ELEVATION myocardial infarctionunfractionated heparin

Identifiers

PMID32543247
PMCPMC8352377
OpenAlexW3034362647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.